An observational study in SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis, sponsored by Nantes University Hospital. Completed at 1 site in France. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Nantes University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Arthritis, Juvenile with a site in France — 18 open to participants now, 21 under way, 9 of them phase 3. Arthritis, Juvenile · France.
Among the 71 studies in Arthritis, Juvenile with a site in France, this one is the 19th largest by enrollment of the 21 observational ones that give a count, is one of 4 that started in 2024, is one of 21 observational ones, and was the 59th registered.
367 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →18 of the 71 studies in Arthritis, Juvenile with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 2–16
Alfasigma S.p.A. · Sites in France, Belgium, Czechia and 6 more countries
Ages 8–18
Alfasigma S.p.A. · Sites in France, Germany, United Kingdom
Ages 8–18
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Novartis Pharmaceuticals · Sites in France, United States, Canada and 5 more countries
Ages 1+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.
This study: 12 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 28
First in 2000; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 120 across 119 observational studies indexed under Arthritis, Juvenile.
Median enrollment 61 across the 50 interventional studies, 274 across the 21 observational. Of the 42 that completed or were terminated, 16 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 71 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 1 study filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
5 of the studies in Arthritis, Juvenile with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07554495Phase 3Alfasigma S.p.A.Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents | 2027-06 |
| NCT07203001Novartis PharmaceuticalsA Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | 2027-04-22 |
| NCT05927454Institut National de la Santé Et de la Recherche Médicale, FranceAcostill ( RaDiCo Cohort) (RaDiCo Acostill) | 2027-07 |
| NCT07077304Assistance Publique - Hôpitaux de ParisEACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases | 2027-08-31 |
| NCT07634354CHU de ReimsSarcopenia and Juvenile Idiopathic Arthritis | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 71 studies in Arthritis, Juvenile with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Since june 2021, vaccination against the SARS-Cov2 virus is recommanded in France to all children from 12 to 18 years old. In the specific population of teenagers living with juvenile arthritis, the vaccine seems to be safe and well tolerated. It has been shown previously that this population has a vaccine coverage lower than the global population even though few datas are available on this topic The aim of this resarch is to study the vaccination coverage against the SARS-Cov2 virus and more specifically the reasons why adolescents were or were not vaccinated in the population of adolescents with juvenile arthitis followed up in Angers, Nantes and Rennes. For this purpose, a review of the medical record will be done and a questionnaire will be adressed to the family of patients in order to collect informations about the disease, the treatments, the motives or obstacles to vaccination. Secondaries end points are safety of the vaccination, consequences on the juvenile arthritis (such as changes in the medication, flare-up of the illness) and the occurence of covid infection after vaccination.
Patients from 12 to 18 years old followed up from juvenile arthritis in 2021 and 2022 at Angers, Nantes and Rennes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Children from 12 to 18 years old followed up for juvenile arthritis in Angers, Nantes and Rennes.
SARS Cov2 vaccination coverage of this population and factors influencing the realization of the vaccination.
Percentage of patients vaccinated
Time frame: From june 2021 to December 2022
Tolerance of the SARS-Cov2 vaccination
Occurrence of any side-effects
Time frame: From june 2021 to December 2022
Effect of the SARS Cov2 vaccination on juvenile arthritis
Occurrence of flare up of the illness, modification of treatment
Time frame: From june 2021 to December 2022
SARS-Cov 2 infection after vaccination
Occurrence and severity of the infection
Time frame: From june 2021 to December 2022
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in Sep 2024, 3 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jun 2025 → Sep 2024 and completion Jun 2025 → Sep 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.